CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 258 enrolled
Drug / intervention
Suzetriginedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05661734
NCT05661734Phase 3Completed
CompareCT.gov

A Phase 3, Single-arm Study Evaluating the Safety and Effectiveness of VX-548 for Acute Pain

Vertex Pharmaceuticals Incorporated·interventional·Posted Dec 22, 2022·Updated Jul 1, 2025

In Brief

A Phase 3 clinical trial evaluating Suzetrigine for Pain. Completed, enrolled 258 participants across 14 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2023202420252026
First PostedDec 22, 2022
Enrollment StartJan 9, 2023
Primary CompletionDec 12, 2023
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 3.5 years ago

Interventions

Suzetriginedrug

Tablets for oral administration.